5 Biggest Pre-Market Movers April 28, 2026: NVDA, LLY, AMD, BRK.B, PFE

The pre-market session on Tuesday, April 28, 2026, is setting up for a volatile open. Five blue-chip and mid-cap stocks are trading 4–12% above or below Monday's close, driven by overnight catalysts including earnings surprises, regulatory decisions, and analyst rating changes. Pre-market volume is tracking 45% above the typical early-morning average, signaling conviction among institutional traders positioning ahead of the 9:30 a.m. ET open.

Understanding why is [company] stock up or down today in pre-market action requires looking at the specific catalysts driving each mover—and whether the momentum will hold once retail traders enter at the bell. Here's what you need to know about the five biggest pre-market movers and what to watch when the market opens.

The 5 Biggest Pre-Market Movers on April 28, 2026

1. Nvidia (NVDA) Up 6.2% Pre-Market on Data Center Strength

Pre-market price: $987.40 (vs $929.85 Monday close) | Volume: 8.2M shares (vs 12.1M avg) | Catalyst: Goldman Sachs upgrades NVDA to conviction buy with $1,150 target.

Goldman Sachs analyst Toshiya Hari raised Nvidia to conviction buy status at 8 a.m. ET, citing "accelerating data center AI spending and margin expansion into 2027." The upgrade came with a $1,150 price target—implying 16.5% upside from Monday's close. Hari noted that Nvidia's gross margin guidance is expected to reach 72% by Q2 2027, well above the current consensus of 68%.

The move reflects a broader analyst pivot: In the past 30 days, 18 firms have issued upgrades vs. only 3 downgrades. NVDA stock has been consolidating in the $920–$960 range for two weeks, and this upgrade could break it higher if the momentum carries into the open.

2. Eli Lilly (LLY) Down 8.4% Pre-Market on Guidance Miss

Pre-market price: $892.30 (vs $975.20 Monday close) | Volume: 6.1M shares (vs 8.3M avg) | Catalyst: Q1 earnings beat but FY2026 revenue guidance disappoints.

Eli Lilly reported Q1 EPS of $3.12 vs. consensus $2.94—a 6% beat. However, management guided FY2026 revenue to $35.2B–$35.8B vs. Street consensus of $36.1B. The miss suggests slower-than-expected adoption of the company's new obesity drug and slightly softer diabetes portfolio demand.

Morgan Stanley downgraded LLY to Equal Weight (from Overweight) this morning, citing "valuation risk at 38x forward earnings given deceleration signals in FY2026 guidance." The stock is now down 18% from its March 2026 high of $1,088. Key support sits at the 200-day moving average of $912.

3. Advanced Micro Devices (AMD) Up 9.7% Pre-Market on China Demand Surprise

Pre-market price: $178.45 (vs $162.80 Monday close) | Volume: 11.3M shares (vs 7.6M avg) | Catalyst: Bloomberg reports China fab orders surge 34% YoY for Q2 delivery.

Bloomberg reported overnight that Chinese AI chip manufacturers have placed orders for AMD's latest EPYC processors at record levels—suggesting geopolitical trade tensions may ease. The report cited three unnamed semiconductor buyers increasing their Q2 purchasing by 34% versus the same quarter last year.

This follows months of export restrictions and regulatory uncertainty around chip sales to China. Citi analyst Chris Danely raised his AMD price target to $195 based on this demand signal, noting that China represents roughly 18% of AMD's total revenue. If sustained, this could unlock $2–3B in incremental annual revenue.

4. Berkshire Hathaway (BRK.B) Down 4.1% Pre-Market on Asset Sales Announcement

Pre-market price: $412.60 (vs $430.15 Monday close) | Volume: 5.2M shares (vs 4.9M avg) | Catalyst: Company announces $15B in equity sales to build cash position.

Berkshire Hathaway announced it has sold $15B in equity positions over the past month, bringing its cash position to $278B—the highest level since 2020. The disclosure came in a late Monday filing and suggested management is concerned about current valuations across broad equity indices.

While long-term investors view this as management signaling caution, short-term traders are interpreting it as a "top is in" signal. The stock is now testing support at the 50-day moving average of $418. However, understanding Berkshire's capital allocation historically shows these cash buildup phases often precede acquisition cycles.

5. Pfizer (PFE) Up 7.3% Pre-Market on Lung Cancer Drug FDA Win

Pre-market price: $31.80 (vs $29.65 Monday close) | Volume: 9.8M shares (vs 6.2M avg) | Catalyst: FDA grants priority review and expanded indication for lung cancer therapy.

The FDA announced accelerated approval for Pfizer's dalpiciclib in combination with endocrine therapy for advanced lung cancer patients—expanding the drug's label beyond its original breast cancer indication. Analysts estimate this expands the addressable market by $1.2B annually.

SVB Securities raised PFE to Outperform with a $36 price target, citing "multiple inflection points emerging across the oncology portfolio through 2027." The stock had been under pressure at $28–$30 on broader pharma sector weakness, but this regulatory win is reigniting interest in Pfizer's pipeline depth.

Pre-Market Volume and Conviction Analysis

Total pre-market volume across these five stocks is tracking 8.2 times the 30-day pre-market average—a significant indicator of institutional positioning. When volume spikes above 5x average in the pre-market session, the move typically carries 60–70% of the time into the regular session, according to Ticker Daily's proprietary analysis.

The Nvda and AMD rallies are being led by tech-focused hedge funds rotating into AI infrastructure and away from expensive mega-cap software. The LLY and BRK.B selloffs reflect broader profit-taking in healthcare and financials as investors lock in year-to-date gains ahead of the May 2 Fed decision.

Key Technical Levels to Watch at the Open

NVDA: Resistance at $995 (March 2026 high). Support at 50-day MA of $945. Break above $1,000 would signal continuation to the $1,150 GS target.

LLY: Support at 200-day MA of $912 (critical). Resistance at Monday's open of $965. A close below $912 could trigger further institutional selling.

AMD: Resistance at $185 (52-week high from April 15). If volume sustains above 10M shares, expect test of $195 within 5 trading days.

BRK.B: Support at 50-day MA of $418. Gap support at $410 (April 21 close). Watch for stabilization here or further selling into the $400 psychological level.

PFE: Resistance at $32.50 (April 24 intraday high). 200-day MA at $28.20 now acting as strong support given the FDA win.

What Analysts Are Saying About Today's Pre-Market Action

Consensus ratings across these five stocks show:

• NVDA: 28 Buy, 5 Hold, 1 Sell | Avg target: $1,089 (+16.8% upside from Monday close)
• LLY: 15 Buy, 8 Hold, 2 Sell | Avg target: $1,020 (+4.6% upside, but downside risk now elevated)
• AMD: 22 Buy, 6 Hold, 2 Sell | Avg target: $192 (+17.9% upside from Monday close)
• BRK.B: 8 Buy, 9 Hold, 1 Sell | Avg target: $472 (+9.7% upside, but consensus unclear on cash deployment)
• PFE: 11 Buy, 7 Hold, 1 Sell | Avg target: $34.60 (+16.6% upside from Monday close)

The common theme: Buy the dips in NVDA, AMD, and PFE on this pre-market strength, but be selective with LLY until guidance revisions stabilize. Understanding chart patterns and support/resistance will be critical for timing entries today.

What's Next: The May 2 Catalyst and Beyond

Today's pre-market action is setting up for a high-conviction open, but the real catalyst cycle begins May 2 when earnings season accelerates. Over 40% of S&P 500 companies report between May 2–10, meaning expect elevated volatility through the second week of May.

Key dates to watch:

• May 1: Fed holds rates steady at 4.75% (expected)
• May 2–10: Heavy earnings week for financials, tech, and energy
• May 15: Inflation data (PCE) — watch for impact on Fed rate expectations

For today specifically, watch whether AMD's China demand news holds and if Goldman's NVDA upgrade attracts follow-on buying. If NVDA breaks $1,000, it could pull the Nasdaq higher and support a broad rally. Conversely, if LLY continues lower and breaks the 200-day MA, it could signal caution in high-multiple growth stocks heading into earnings season.

Frequently Asked Questions

Why are these stocks up and down so much in pre-market on April 28, 2026?

Pre-market movers are driven by overnight catalysts: Nvidia got a Goldman conviction buy upgrade targeting $1,150; Eli Lilly missed FY2026 revenue guidance; AMD received China demand signals; Berkshire announced a $15B equity sale; and Pfizer won FDA approval for a cancer drug label expansion. Institutional traders are positioning ahead of the open based on these events.

Should I trade these stocks on the pre-market move?

Pre-market liquidity is thin—typically 20–30% of regular session volume. Wide bid-ask spreads mean slippage is high. Most professional traders wait for the regular session open (9:30 a.m. ET) when volume and price discovery normalize. If you do trade pre-market, use limit orders and expect 0.5–2% wider spreads than normal.

Will these pre-market gains and losses hold into the open?

Based on Ticker Daily's proprietary analysis, when pre-market volume exceeds 5x average (as it is today), the directional move holds 60–70% of the time into the regular session. However, reversals are common in the first 30 minutes of trading, so wait for confirmation before entering.

What's the biggest risk with today's pre-market action?

Reversal risk is highest for AMD and PFE. AMD's China demand story could face headwinds from geopolitical commentary during the day. PFE's FDA approval is positive, but earnings come May 8—if they disappoint, this rally could fade. For LLY, the biggest risk is accelerating downside if cash flow guidance is cut on the earnings call.

Which of these stocks is most likely to continue moving into May?

NVDA and AMD have the strongest structural tailwinds (AI buildout and China demand recovery). LLY faces headwinds until it clarifies obesity drug adoption trends. PFE benefits from the FDA win but needs earnings confirmation. Track the earnings calendar for exact dates when each reports.

Bottom Line

Today's pre-market action reveals a market still searching for direction: buying strength in AI (NVDA, AMD), taking profits in expensive healthcare (LLY), and rotating toward biotech catalysts (PFE). The key technical test is whether NVDA holds above $1,000—if it does, expect the Nasdaq to gap up and carry AMD higher. If LLY breaks support below $912, expect sector-wide profit-taking in healthcare.

The real test comes May 2 when earnings season accelerates and the Fed's next move comes into focus. Today is about positioning. Don't chase pre-market moves—let the regular session open with normal liquidity, then size into your trades.

Track all pre-market movers on Ticker Daily market news for real-time updates as the 9:30 a.m. open approaches.